<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1190">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145660</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-2021C-257</org_study_id>
    <nct_id>NCT05145660</nct_id>
  </id_info>
  <brief_title>Optimization of Cervical Nodal Clinical Tumor Volume for Early and Medium Stage Nasopharyngeal Carcinoma</brief_title>
  <official_title>Optimization of Cervical Nodal Clinical Tumor Volume for Early and Medium Stage Nasopharyngeal Carcinoma: a Prospective, Multicenter, Randomized Controlled Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun-Lin Yi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regional failure rate of early to mid-stage nasopharyngeal carcinoma is low and&#xD;
      recurrence is mainly in high-dose areas within the target area. The purpose of this study was&#xD;
      to investigate whether a strategy of irradiating the affected site to narrow the clinical&#xD;
      target area of high-risk lymph nodes (ISI) could significantly reduce treatment-related&#xD;
      toxicities without compromising regional control rates compared with a conventional regimen&#xD;
      (ERI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the application of IMRT has led to significant improvements in survival in early to&#xD;
      mid-stage nasopharyngeal carcinoma (NPC), late toxicities of radiotherapy still severely&#xD;
      affect patients' quality of life. The strategies of reducing the intensity of radiotherapy to&#xD;
      alleviate late injuries have become the central focus of current research. Numerous studies&#xD;
      have demonstrated the safety and effectiveness of reducing the volume of high-risk clinical&#xD;
      target area (CTV) of the primary nasopharyngeal tumor. However, for lymph nodes with a high&#xD;
      metastatic rate of 60%-80%, there are no studies investigating how to reduce their high-risk&#xD;
      CTV. And the Guidelines haven't recommended optimal delination strategies. Therefore, whether&#xD;
      ISI is a better choice for early to mid-stage NPC has not been clarified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>regional recurrence-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Time（months） from diagnosis to regional recurrence；</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>Time（months） from diagnosis to death, regardless of cause；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progress free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Time（months） from diagnosis to progression，including recurrence，distant metastasis and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Time（months） from diagnosis to first distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>accumulated late toxicities</measure>
    <time_frame>3-year</time_frame>
    <description>Number of patients（only those with over 1-year follow-up are included） with late treatment-related adverse events（e.g.，subcutaneous fibrosis and hearing impairmen）as assessed by CTCAE vversion 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental: involved site irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTVn1=GTVnd+10mm expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elective region irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTVn1= the whole levels where positive lymph nodes are located （the involved levels）+ plus at least ipsilateral one level below the involved levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiotherapy (IMRT) with reduced-volume</intervention_name>
    <description>GTVnd: 69.96Gy/2.12Gy/33F. CTVp1: 60.06Gy/1.82Gy/33F. CTVn1: 60.06Gy/1.82Gy/33F. CTVn2: 50.96Gy/1.82Gy/28F.</description>
    <arm_group_label>Experimental: involved site irradiation</arm_group_label>
    <arm_group_label>elective region irradiation</arm_group_label>
    <other_name>intensity-modulated radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (DDP)</intervention_name>
    <description>DDP 100 mg/m2, d1,22,43</description>
    <arm_group_label>Experimental: involved site irradiation</arm_group_label>
    <arm_group_label>elective region irradiation</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 to 70 years, regardless of gender.&#xD;
&#xD;
          -  histologically confirmed nasopharyngeal carcinoma.&#xD;
&#xD;
          -  T1-3N0-2 (stageII-III) with metastatic lymph nodes ≤ 4 cm in maximum diameter and no&#xD;
             extra nodal extension（ENE）.&#xD;
&#xD;
          -  KPS score ≥ 70.&#xD;
&#xD;
          -  completed pre-treatment CT/MRI imaging data (including functional MRI sequences) with&#xD;
             measurable tumor lesions.&#xD;
&#xD;
          -  the first course of therapy.&#xD;
&#xD;
          -  expected survival longer than 6 months.&#xD;
&#xD;
          -  laboratory criteria: Hb &gt;120g/L, white blood cells ≥4x109 /L, ≥100x109 /L, liver and&#xD;
             kidney function indicators within the upper limit of normal values 1.25 more range; no&#xD;
             hearing impairment.&#xD;
&#xD;
          -  can understand the study and have signed the informed consent form.&#xD;
&#xD;
          -  have the conditions for follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  maximum diameter of metastatic lymph nodes &gt; 4 cm.&#xD;
&#xD;
          -  gross melted Cervical lymph nodes or extra nodal extension.&#xD;
&#xD;
          -  jumping metastases of cervical lymph nodes.&#xD;
&#xD;
          -  T4 or N3 stage.&#xD;
&#xD;
          -  has other malignancies (other than stage I non-melanotic skin cancer or carcinoma in&#xD;
             situ of the cervix).&#xD;
&#xD;
          -  has received other tumor-related treatment.&#xD;
&#xD;
          -  pregnant or breastfeeding, and women of childbearing age.&#xD;
&#xD;
          -  undergoing trials of other drugs.&#xD;
&#xD;
          -  with severe comorbidities, including myocardial infarction, severe arrhythmias, severe&#xD;
             cerebrovascular disease, ulcer disease, psychiatric disorders and uncontrollable&#xD;
             diabetes mellitus.&#xD;
&#xD;
          -  do not have the condition of regular follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junlin Yi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlin Yi, doctor</last_name>
    <phone>13661217998</phone>
    <email>junlinyi@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun-Lin Yi, MD</investigator_full_name>
    <investigator_title>Radiotherapy director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

